Company Encyclopedia
View More
name
iShares Biotechnology ETF
IBB.US
News
View More

Chmn Lewis Files To Sell 10,699 Of Insmed Inc [INSM]

Lewis William H, Chairman of Insmed Inc, filed a Form 144 with the SEC to sell 10,699 shares on December 4, 2025, through Merrill Lynch & Co Inc. The sale is executed under a prearranged trading plan (10b5-1).

Reuters·
US
INSM
-0.84%
Reuters·
US
INSM
-0.84%

IQVIA Holdings Inc. Stock Underperforms Thursday When Compared To Competitors

IQVIA Holdings Inc. stock fell 1.02% to $224.92 on Thursday, underperforming compared to competitors like HCA Healthcare and Centene Corp. The stock is 4% below its 52-week high of $234.30. The S&P 500 rose 0.11%, while the Dow Jones fell 0.07%. The data was compiled on December 4, 2025, by MarketWatch.

Dow Jones·
US
IQV
-1.02%
Dow Jones·
US
IQV
-1.02%

Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors

Gilead Sciences Inc. (GILD) shares fell 1.90% to $122.62 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Gilead's stock is 4.72% below its 52-week high. Trading volume was 4.9M, below the 50-day average of 7.3M. Competitors' performances: Johnson & Johnson (JNJ) fell 1.39%, Pfizer Inc. (PFE) rose 0.51%, and Abbott Laboratories (ABT) rose 0.09%. Data source: Dow Jones Market Data, FactSet. Compiled December 4, 2025.

Dow Jones·
US
GILD
-1.90%
Dow Jones·
US
GILD
-1.90%

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors

Amgen Inc. shares fell 1.52% to $340.16 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Amgen's stock ended a two-day winning streak and closed 1.80% below its 52-week high. Competitors' performances varied: Johnson & Johnson fell 1.39%, Pfizer rose 0.51%, and AbbVie fell 0.66%. Trading volume was 3.4 million, above the 50-day average of 2.5 million.

Dow Jones·
US
JNJ
-1.39%
US
AMGN
-1.52%
US
ABBV
-0.66%
Dow Jones·
US
JNJ
-1.39%
US
AMGN
-1.52%
US
ABBV
-0.66%

Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation?

Alnylam Pharmaceuticals (ALNY) stock has surged 12% in the past month and nearly doubled over the past year, raising questions about its valuation. The stock is priced at $473, slightly below Wall Street's target of $489, suggesting a modest 3.2% undervaluation. However, a DCF model indicates a 21% undervaluation with a fair value near $601. The growth is driven by AMVUTTRA's uptake and RNAi therapies' market expansion. Risks include pricing pressure and high R&D costs. Investors are advised to consider other innovative healthcare stocks.

Simplywall·
US
ALNY
-1.68%
Simplywall·
US
ALNY
-1.68%
© 2025 Longbridge｜Disclaimer